Your browser doesn't support javascript.
loading
Substrate-derived Sortase A inhibitors: targeting an essential virulence factor of Gram-positive pathogenic bacteria.
Abujubara, Helal; Hintzen, Jordi C J; Rahimi, Shadi; Mijakovic, Ivan; Tietze, Daniel; Tietze, Alesia A.
Afiliação
  • Abujubara H; Department of Chemistry and Molecular Biology, Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg Kemigården 4 412 96 Göteborg Sweden alesia.a.tietze@gu.se.
  • Hintzen JCJ; Department of Chemistry and Molecular Biology, Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg Kemigården 4 412 96 Göteborg Sweden alesia.a.tietze@gu.se.
  • Rahimi S; Division of Systems & Synthetic Biology, Department of Biology and Biological Engineering, Chalmers University of Technology Kemivägen 10 412 96 Göteborg Sweden.
  • Mijakovic I; Division of Systems & Synthetic Biology, Department of Biology and Biological Engineering, Chalmers University of Technology Kemivägen 10 412 96 Göteborg Sweden.
  • Tietze D; The Novo Nordisk Foundation, Center for Biosustainability, Technical University of Denmark DK-2800 Kongens Lyngby Denmark.
  • Tietze AA; Department of Chemistry and Molecular Biology, Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg Kemigården 4 412 96 Göteborg Sweden alesia.a.tietze@gu.se.
Chem Sci ; 14(25): 6975-6985, 2023 Jun 28.
Article em En | MEDLINE | ID: mdl-37389257
The bacterial transpeptidase Sortase A (SrtA) is a surface enzyme of Gram-positive pathogenic bacteria. It has been shown to be an essential virulence factor for the establishment of various bacterial infections, including septic arthritis. However, the development of potent Sortase A inhibitors remains an unmet challenge. Sortase A relies on a five amino acid sorting signal (LPXTG), by which it recognizes its natural target. We report the synthesis of a series of peptidomimetic inhibitors of Sortase A based on the sorting signal, supported by computational binding analysis. By employing a FRET-compatible substrate, our inhibitors were assayed in vitro. Among our panel, we identified several promising inhibitors with IC50 values below 200 µM, with our strongest inhibitor - LPRDSar - having an IC50 of 18.9 µM. Furthermore, it was discovered that three of our compounds show an effect on growth and biofilm inhibition of pathogenic Staphylococcus aureus, with the inclusion of a phenyl ring seemingly key to this effect. The most promising compound in our panel, BzLPRDSar, could inhibit biofilm formation at concentrations as low as 32 µg mL-1, manifesting it as a potential future drug lead. This could lead to treatments for MRSA infections in clinics and diseases such as septic arthritis, which has been directly linked with SrtA.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article